Given the diverse stakeholders in attendance, the hallway conversations at the ACO and Emerging Healthcare Delivery Coalition Spring 2015 meeting in San Diego, California, were just as interesting as the sessions, according to Anthony D. Slonim, MD, DrPH, president and chief executive officer for Renown Health, and co-chair of Coalition.
Given the diverse stakeholders in attendance, the hallway conversations at The American Journal of Managed Care's ACO and Emerging Healthcare Delivery Coalition Spring 2015 meeting in San Diego, California, were just as interesting as the sessions, according to Anthony D. Slonim, MD, DrPH, president and chief executive officer for Renown Health, and co-chair of Coalition.
At the third live ACO Coalition event, there was more focus on disease-specific focus areas, he said, and this is incredibly important as the healthcare industry segments the population.
"I found that the AJMC Coalition has been a great opportunity for me to network professionally, and learn from other people who are doing the same kinds of work that I am," Dr Slonim said.
Learn more about the ACO Coalition and find out how to join and attend future events: click here.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More